Currently, sunitinib, a TKI that inhibits KIT, PDGFRA, PDGFRB, Fms-like tyrosine kinase-3 receptor, RET, and vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, is the second line TKI of choice in patients with generalized disease progression who have failed imatinib dose escalation or who are imatinib intolerant

Posted on by Courtney Roberts

Currently, sunitinib, a TKI that inhibits KIT, PDGFRA, PDGFRB, Fms-like tyrosine kinase-3 receptor, RET, and vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, is the second line TKI of choice in patients with generalized disease progression who have failed imatinib dose escalation or who are imatinib intolerant. kinase Continue Reading